Figure 4From: CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy Modified CD200 antagonists enhance survival. A. EMT6 tumor bearing mice were vaccinated with tumor lysate, CpG +/- CD200 antagonist 4004, 4013 or 6059. B. New CD200R antagonist A12-6059 enhances survival. Log-rank analysis was used for survival.Back to article page